We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
Read MoreHide Full Article
bluebird bio, Inc. (BLUE - Free Report) announced that it has received a $175 million five-year, term loan facility from Hercules Capital, Inc. (HTGC - Free Report) . The funding will extend bluebird’s cash runaway by two years. The company’s shares rose 1.4% on the news.
Per the terms of the agreement, bluebird will get the term loans in four tranches. The first tranche of $75 million was drawn upon the closing of the transaction. BLUE will be eligible to draw two additional tranches of $25 million each, subject to the achievement of commercial milestones.
If all three tranches totaling $125 million are executed, the transaction is expected to extend bluebird’s cash runway through the first quarter of 2026. It will be based on current plans and the launch trajectory of its three gene therapies — Lyfgenia for sickle cell disease, Zynteglo for beta-thalassemia and Skysona for cerebral adrenoleukodystrophy.
The agreement states that a fourth tranche of up to $50 million may be available at the sole discretion of Hercules.
BLUE will be responsible for paying only the interest on any amount borrowed during the first three years of the five-year term. Any outstanding balance as of Apr 1, 2027, will be amortized over the remaining life of the loan.
The funding gives bluebird the much-needed funds as it looks to commercialize its three gene therapies.
We remind investors that the FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy on Sep 16, 2022. The company received PRVs with the FDA approval of these two gene therapies.
Shares of bluebird have plunged 67.7% in the past year compared with the industry’s decline of 8%.
Image Source: Zacks Investment Research
Shares of the company tanked in December after it raised additional equity. The company offered 83.3 million shares of its common stock at an offer price of $1.50 per share.
The stock has been under pressure, particularly after the FDA recently approved its third gene therapy, lovotibeglogene autotemcel (lovo-cel), under the brand name Lyfgenia, for the treatment of sickle cell disease (SCD) in patients aged 12 years and older with a history of vaso-occlusive events.
This was primarily because of the boxed warning of hematologic malignancy issued with Lyfgenia’s label. Some patients developed blood cancer when being treated with Lyfgenia.
Hence, bluebird will need to monitor patients closely for evidence of malignancy through complete blood counts, at least every six months, and integration site analysis at months six, 12 and as warranted.
Moreover, the FDA concurrently approved Vertex Pharmaceuticals (VRTX - Free Report) and CRISPR Therapeutics’ (CRSP - Free Report) exagamglogene autotemcel, a CRISPR/Cas9 genome-edited cell therapy, for the treatment of SCD in patients aged 12 years and older with recurrent vaso-occlusive crises.
Exagamglogene autotemcel was approved under the brand name Casgevy, making it the first FDA-approved treatment to utilize a type of novel genome editing technology.
Approval of another gene therapy for the same indication will make it challenging for bluebird to gain market shares.
Also, BLUE has priced Lyfgenia at $3.1 million per dose. Vertex and CRISPR's gene therapy will cost $2.2 million each for every dose.
bluebird also did not receive a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the review. Management had expected to receive the same as it had earlier received two PRVs under an FDA program intended to encourage the development of treatments for rare pediatric diseases.
Image: Bigstock
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
bluebird bio, Inc. (BLUE - Free Report) announced that it has received a $175 million five-year, term loan facility from Hercules Capital, Inc. (HTGC - Free Report) . The funding will extend bluebird’s cash runaway by two years. The company’s shares rose 1.4% on the news.
Per the terms of the agreement, bluebird will get the term loans in four tranches. The first tranche of $75 million was drawn upon the closing of the transaction. BLUE will be eligible to draw two additional tranches of $25 million each, subject to the achievement of commercial milestones.
If all three tranches totaling $125 million are executed, the transaction is expected to extend bluebird’s cash runway through the first quarter of 2026. It will be based on current plans and the launch trajectory of its three gene therapies — Lyfgenia for sickle cell disease, Zynteglo for beta-thalassemia and Skysona for cerebral adrenoleukodystrophy.
The agreement states that a fourth tranche of up to $50 million may be available at the sole discretion of Hercules.
BLUE will be responsible for paying only the interest on any amount borrowed during the first three years of the five-year term. Any outstanding balance as of Apr 1, 2027, will be amortized over the remaining life of the loan.
The funding gives bluebird the much-needed funds as it looks to commercialize its three gene therapies.
We remind investors that the FDA approved Zynteglo for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions on Aug 17, 2022, and Skysona for treating early, active cerebral adrenoleukodystrophy on Sep 16, 2022. The company received PRVs with the FDA approval of these two gene therapies.
Shares of bluebird have plunged 67.7% in the past year compared with the industry’s decline of 8%.
Image Source: Zacks Investment Research
Shares of the company tanked in December after it raised additional equity. The company offered 83.3 million shares of its common stock at an offer price of $1.50 per share.
The stock has been under pressure, particularly after the FDA recently approved its third gene therapy, lovotibeglogene autotemcel (lovo-cel), under the brand name Lyfgenia, for the treatment of sickle cell disease (SCD) in patients aged 12 years and older with a history of vaso-occlusive events.
This was primarily because of the boxed warning of hematologic malignancy issued with Lyfgenia’s label. Some patients developed blood cancer when being treated with Lyfgenia.
Hence, bluebird will need to monitor patients closely for evidence of malignancy through complete blood counts, at least every six months, and integration site analysis at months six, 12 and as warranted.
Moreover, the FDA concurrently approved Vertex Pharmaceuticals (VRTX - Free Report) and CRISPR Therapeutics’ (CRSP - Free Report) exagamglogene autotemcel, a CRISPR/Cas9 genome-edited cell therapy, for the treatment of SCD in patients aged 12 years and older with recurrent vaso-occlusive crises.
Exagamglogene autotemcel was approved under the brand name Casgevy, making it the first FDA-approved treatment to utilize a type of novel genome editing technology.
Approval of another gene therapy for the same indication will make it challenging for bluebird to gain market shares.
Also, BLUE has priced Lyfgenia at $3.1 million per dose. Vertex and CRISPR's gene therapy will cost $2.2 million each for every dose.
bluebird also did not receive a Rare Pediatric Disease Priority Review Voucher (PRV) as part of the review. Management had expected to receive the same as it had earlier received two PRVs under an FDA program intended to encourage the development of treatments for rare pediatric diseases.
Zacks Rank
bluebird currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.